Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 7/20 | 0.34 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156214 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL8442314 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL1707472 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL2389036 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL15326061 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL23560381 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL2725276 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL6515101 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL22277214 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL19462783 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150955-B2 | Iodine compositions | DERMALIQ THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | claimed |
| CN-110678207-B | Iodine composition | 德马利克治疗公司 | 2024-08-02 | — | — | CN | claimed |
| CN-117897439-A | Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| CN-117897440-A | Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| EP-3612228-B1 | IODINE COMPOSITIONS | DERMALIQ THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | claimed |
| US-20220152096-A1 | IODINE COMPOSITIONS | DERMALIQ THERAPEUTICS, INC. | 2022-05-19 | — | — | US | claimed |
| US-11273174-B2 | Iodine compositions | NOVALIQ GMBH (DE) | 2022-03-15 | — | — | US | claimed |
| US-12599607-B2 | Pharmaceutical compositions comprising timolol | NOVALIQ GMBH (DE) | 2026-04-14 | — | — | US | disclosed |
| US-12569452-B2 | Ophthalmic compositions comprising F6H8 | NOVALIQ GMBH (DE) | 2026-03-10 | — | — | US | disclosed |
| WO-2025133214-A1 | OPHTHALMIC POLYPEPTIDE COMPOSITIONS FOR THE TREATMENT OF POSTERIOR EYE DISORDERS | NOVALIQ GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-120022260-A | Ophthalmic compositions comprising F6H8 | 诺瓦利克有限责任公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119909046-A | Ophthalmic compositions comprising F6H8 | 诺瓦利克有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12150955-B2 | Iodine compositions | DERMALIQ THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20220152096-A1 | IODINE COMPOSITIONS | DERMALIQ THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11273174-B2 | Iodine compositions | NOVALIQ GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| EP-3619186-B1 | PROCESS FOR THE PRODUCTION OF SEMIFLUORINATED ALKANES | NOVALIQ GMBH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200140358-A1 | PROCESS FOR THE PRODUCTION OF SEMIFLUORINATED ALKANES | NOVALIQ GMBH (DE) | 2020-05-07 | — | — | US | disclosed |
| US-8110540-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-02-07 | — | — | US | disclosed |
| US-20100183650-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2010-07-22 | — | — | US | disclosed |
| US-7687455-B2 | comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183650-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | CES2 1869/4885LPAR1 978/4885LPAR3 1102/4885 |
| US-20200140358-A1 | PROCESS FOR THE PRODUCTION OF SEMIFLUORINATED ALKANES | ALK, FASN, CYP4F2 | CES2 325/4885LPAR1 1721/4885LPAR3 1449/4885 |
| US-12569452-B2 | Ophthalmic compositions comprising F6H8 | F8, CFH, FAAH2 | CES2 1666/4885LPAR1 1236/4885LPAR3 835/4885 |
| US-12599607-B2 | Pharmaceutical compositions comprising timolol | ADRB1, ADRA1D, ADRB2 | CES2 3291/4885LPAR1 811/4885LPAR3 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.